On April 16, 2026 Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, reported that it has entered into definitive agreements for the purchase and sale of 2,222,223 shares of its common stock (or pre-funded warrants in lieu thereof), Series I warrants to purchase up to an aggregate of 2,222,223 shares of common stock and short-term Series J warrants to purchase up to an aggregate of 2,222,223 shares of common stock, at a purchase price of $2.25 per share (or pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $2.00 per share and will be exercisable immediately upon issuance. The Series I warrants will expire five years after the effective date of the Resale Registration Statement (as defined below) and the short-term Series J warrants will expire eighteen months after the effective date of the Resale Registration Statement.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The aggregate gross proceeds to the Company from the offering are expected to be approximately $5 million before deducting placement agent fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the Series I warrants and the short-term Series J warrants, if fully exercised on a cash basis, will be approximately $8.9 million. No assurance can be given that any of the warrants will be exercised, or that the Company will receive cash proceeds from the exercise of the warrants. The closing of the offering is expected to occur on or about April 17, 2026, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for product development, working capital and general corporate purposes.

The securities described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act") and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants sold in the offering, have not been registered under the Securities Act or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to a registration rights agreement, the Company has agreed to file one or more registration statements with the SEC covering the resale of the unregistered securities to be issued in the offering (the "Resale Registration Statement").

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

(Press release, Enveric Biosciences, APR 16, 2026, View Source [SID1234664469])

On April 16, 2026 Nula Therapeutics (previously called Apollo Alpha), a biotechnology company developing a new class of medicines targeting the nuclear envelope of cells in order to treat chronic disease and extend healthspan, reported its launch with an up to $20 million award from the U.S. Advanced Research Projects Agency for Health (ARPA-H) under its PROSPR (PROactive Solutions for Prolonging Resilience) program, bringing total funding to more than $30 million. Additionally, Nula Therapeutics announced its plans for a phase 1b clinical trial with its lead, small molecule asset NLT-101 in Q4, 2026 in metabolic dysfunction, as the company works to address a broad spectrum of chronic, age-related diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Nula is built on a fundamental insight: the integrity of the nuclear envelope, the structure that organizes DNA and governs gene expression, plays a central role in maintaining cellular identity and metabolic homeostasis. Degeneration or dysfunction of the nuclear envelope results in metabolic dysfunction and age-related decline. Restoring function of the nuclear envelope represents a novel strategy to treat chronic disease biology. By developing targeted small molecules that restore the nuclear envelope, Nula aims to treat unmet patient needs and extend healthspan across conditions including metabolic disease, metabolic dysfunction-associated steatohepatitis (MASH), and neurodegeneration. With a clinic-ready asset, NLT-101, and a clinical study planned to begin later this year, Nula is positioned to generate meaningful data in support of its vision of next-generation medicines for chronic diseases.

"The nuclear envelope is one of the most fundamental and underexplored regulators of cellular health, and we believe it represents one of the most promising frontiers in medicine," said Christopher R. Shepard, Ph.D., Chief Executive Officer of Nula Therapeutics and Principal Investigator on the Award. "Today’s announcement marks not only our debut as a company, but a significant external validation of our science. The ARPA-H award will allow us to rigorously explore NLT-101’s potential to preserve functional health across multiple organ systems, while our core clinical program in metabolic dysfunction moves forward in parallel."

Nils Regge, Founder and General Partner at Apollo Health Ventures, added, "PROSPR is highly relevant to our mission at Apollo Health Ventures. Establishing the evidence base and a clear regulatory pathway for therapeutics that improve healthspan, intrinsic capacity, and functional resilience is foundational to the field of longevity biotechnology. We are excited to see Nula’s program paving the way, and we look forward to seeing the company demonstrate the potential of NLT-101 beyond its initial clinical indication, with implications across multiple age-related conditions."

About the ARPA-H PROSPR Award

Under the ARPA-H PROSPR program, Nula Therapeutics will pursue a concurrent work stream designed to evaluate NLT-101’s impact on intrinsic capacity – a composite measure of physical, cognitive, sensory, and psychological function across multiple organ systems. Specific program objectives include:

Evaluation of NLT-101 in aged preclinical models across multiple intrinsic capacity domains
Advancement of NLT-101 through translational pharmacology and IND-enabling studies
Development of biomarker-driven strategies to quantify functional preservation and therapeutic response
This program integrates functional performance measures and systems-level biomarker analysis to build a robust translational dataset supporting potential clinical development in healthspan-focused indications, while Nula’s primary clinical development program in metabolic dysfunction advances along a well-established regulatory path.

The program culminates in a 12-month, randomized, placebo-controlled clinical study in healthy older adults, with Intrinsic Capacity as the primary endpoint. By assessing intrinsic capacity alongside emerging surrogate biomarkers, the initiative aims to help define measurable, regulatory-relevant endpoints for therapeutics targeting aging biology and functional resilience, potentially accelerating and streamlining future development programs.

(Press release, Nula Therapeutics, APR 16, 2026, View Source [SID1234664463])

On April 16, 2026 Adlai Nortye Ltd. (Nasdaq: ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, reported that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $150.0 million, before deducting placement agent fees and other private placement expenses.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The oversubscribed transaction includes participation from both new and existing institutional investors. New investors include Soleus Capital, Perceptive Advisors, ADAR1 Capital Management, MPM BioImpact, Octagon Capital, Eventide Asset Management and Kalehua Capital, DAFNA Capital Management, etc., with additional participation from existing investors including Cormorant Asset Management, Columbia Threadneedle Investments, Balyasny Asset Management, Casdin Capital and Squadron Capital Management, Superstring Capital Management, etc.

In the private placement, the Company is selling 11,320,755 ADSs, at a price of $13.25 per ADS, which equals the closing price of the Company’s ADSs on the Nasdaq Global Market on April 15, 2026. The private placement is expected to close on April 17, 2026, subject to the satisfaction of customary closing conditions.

Carsten Lu, Chairman and Chief Executive Officer of Adlai Nortye, said, "We are delighted to have brought together this group of high-quality healthcare investors to support Adlai Nortye and our innovative, potentially best-in-class RAS-targeting therapies. We thank our investors for their confidence in the broad potential of our RAS-targeting pipeline and our next-generation ADC payload platform, RASiCA, as well as their commitment to our mission to transform deadly cancer into a chronic and eventually curable disease."

Leerink Partners, Cantor, Lucid Capital Markets, H.C. Wainwright & Co. and Jones are acting as joint placement agents for the private placement.

The securities being issued and sold in this private placement have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws, and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Adlai Nortye has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the ADSs issued in the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, Adlai Nortye Biopharma, APR 16, 2026, View Source [SID1234664462])

On April 16, 2026 STORM Therapeutics Ltd. (STORM), the clinical stage company targeting RNA modifications to reprogram cells and develop novel cancer therapies, reported a successful $56 million Series C financing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The proceeds will support the advancement of STC-15, a first‑in‑class, oral small-molecule inhibitor of METTL3, including funding the Company’s Phase 2 monotherapy study in selected sarcoma indications, in which the first patient has now been successfully dosed. Sarcoma is a form of cancer that arises in bone or soft tissues, including muscle, fat, cartilage, blood vessels, and other connective or supportive tissue. This study is designed to support a potential accelerated regulatory approval pathway for STC-15 and to establish a foundation for subsequent clinical development across additional oncology indications.

STC-15 inhibits METTL3, an RNA-modifying enzyme involved in the regulation of cancer stem cell differentiation, a critical process in the development of sarcomas and other malignancies. In a Phase 1 monotherapy study, STC-15 demonstrated durable tumor regression across multiple sarcoma subtypes, underscoring its potential to target and reprogram progenitor cells that transform into cancer cells. These results will be presented at an upcoming medical conference in 2026.

Jerry McMahon, Chief Executive Officer of STORM Therapeutics, said: "Advancing our first‑in‑class METTL3 inhibitor, STC-15, into Phase 2 clinical development marks a pivotal breakthrough in tackling cancers characterized by aberrant cell differentiation. This milestone highlights our scientific innovation and the potential to create new therapeutic options for patients with substantial unmet needs. We are grateful for the steadfast support from our investors and are encouraged by the robust durability and activity demonstrated with STC-15 in Phase 1 studies. As we begin our Phase 2 trial, our focus remains on addressing critical unmet needs in sarcoma for the benefit of patients."

Jonathan Trent, MD of the University of Miami, Sylvester Comprehensive Cancer Center, commented: "The launch of the Phase 2 trial for STC-15 represents a significant advancement in the treatment landscape for sarcoma and other tumors driven by METTL3. STC-15’s novel mechanism of action targets sarcomas at their vulnerability, reprogramming malignant cells toward cell cycle arrest and apoptosis. We are hopeful that this research will yield meaningful insights and, ultimately, new therapeutic avenues for patients with pressing unmet needs."

STORM’s sarcoma program builds on previous clinical and translational research in epitranscriptomic regulation, emphasizing the importance of RNA-modifying enzymes in the maintenance of stem cell‑derived tumors and their potential application in broader settings. METTL3 methylates mRNA, influencing the differentiation processes of connective tissues and other cell types. Sarcomas arise from transformed mesenchymal stem cells as they progress into malignant connective tissue cells, accounting for 1% of adult cancers and 15% of pediatric cancers. Due to the frequent absence of driver mutations or immunogenic features amenable to standard treatments, sarcomas depend on METTL3-driven methylation for growth and survival. The Phase 2 trial will assess the anti-tumor effects of inhibiting mRNA methylation in sarcomas.

The financing was funded by existing investors, M Ventures, Pfizer Ventures, Taiho Ventures LLC, IP Group plc, the UTokyo Innovation Platform Co., Ltd. (UTokyo IPC), and Fast Track Initiative (FTI).

(Press release, STORM Therapeutics, APR 16, 2026, View Source [SID1234664461])

On April 16, 2026 TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for braincancer and eye diseases, reported a Nature Communications article on the results from the Phase 1/2 expansion Arm A cohort of the GLORIA trial testing NOX-A12 + radiotherapy + anti-VEGF "triple therapy" in glioblastoma patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The article in the scientific peer-reviewed high-impact journal, Nature Communications, describes results of the expansion cohort Arm A in TME Pharma’s Phase 1/2 GLORIA trial. In this arm, chemotherapy-resistant (MGMT unmethylated) glioblastoma patients with residual tumor after surgery received NOX-A12 + radiotherapy + anti-VEGF (bevacizumab) "Triple Therapy". The authors noted that overall survival (OS) of patients receiving NOX-A12 Triple Therapy significantly outperformed two different cohorts of similar patients external to the trial who received standard of care treatment, and further noted that due to the conservative trial design, the study "likely underestimates survival compared with most contemporary trials."

As already disclosed in the March 5, 2024 press release, the GLORIA trial has been amended to allow inclusion of 100 additional patients in a randomized, controlled Phase 2 part of the trial composed of 5 additional arms (Expansion Group Arms D through H) to assess three different doses of NOX-A12 in the Triple Therapy, one dose of NOX-A12 + radiotherapy and standard of care. It is planned to initiate this Phase 2 part of the trial once appropriate partnerships are in place.

The findings described in the publication demonstrate the potential and value of TME Pharma’s NOX-A12 asset. TME Pharma remains confident in its strategy to search for a strategic partner to outlicense NOX-A12with the goal of bringing NOX-A12 to market authorization. As communicated on January 5, 2026, TME Pharma continues its active discussions with potential partners for the NOX-A12 program.

As indicated in its press release of March 9, 2026, TME Pharma’s financial runway now extends to Q2-2027, providing the company with the flexibility to identify the optimal partnership for NOX-A12.

Diede van den Ouden, CEO of TME Pharma, said: "We are encouraged by the publication in Nature Communications, which underscore the scientific validity of our approach. We remain fully committed to bringing NOX-A12 to success and believe that a strategic partnership is the optimal path forward. With our extended cash runway, we are well-positioned to continue our negotiations with potential partners."

(Press release, TME Pharma, APR 16, 2026, View Source [SID1234664460])